Data from a phase II study were presented at ASCO 2019, focusing on responses among women with BRCA wild-type ovarian cancer to olaparib.
This FDA confirmatory phase III study evaluated olaparib vs treatment of physician’s choice in BRCA-mutated, platinum-sensitive relapsed ovarian cancer.
The phase II AVANOVA trial examined PFS in advanced ovarian cancer patients who received a PARP inhibitor plus bevacizumab.
In this study from Johns Hopkins, it was found that women with ovarian cancer had better outcomes after the implementation of the Affordable Care Act.
Researchers tested the angiogenesis inhibitor trebananib combined with the standard of care in patients with advanced ovarian cancer.
A trial compared two intraperitoneal chemotherapy regimens and an intravenous regimen for newly diagnosed advanced ovarian carcinoma.
The phase II KEYNOTE-158 basket trial evaluated single-agent pembrolizumab in patients with previously treated advanced cervical cancer.
Researchers conducted the QUADRA trial to examine if niraparib could improve outcomes in heavily pretreated patients with ovarian cancer.
In this study, researchers aimed to further characterize differences in hospice use in a cohort of ovarian cancer patients.
The TWiST analysis of the phase III ENGOT-OV16/NOVA trial evaluated the time without symptoms or toxicity for niraparib vs placebo in patients with recurrent ovarian cancer.